Creative Planning Myovant Sciences Ltd. Transaction History

Creative Planning

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 03, 2022	BUY	$11.6 - $20.44 $316,042 - $556,887	27,245 New	27,245 $489,000
Q1 2021 Apr 30, 2021	SELL	$20.46 - $25.18 $427,614 - $526,262	-20,900 Closed	0 $0
Q4 2020 Jan 29, 2021	BUY	$13.8 - $27.62 $44,160 - $88,384	3,200 Added 18.08%	20,900 $577,000
Q3 2020 Nov 05, 2020	BUY	$14.05 - $22.6 $248,685 - $400,020	17,700 New	17,700 $249,000
Q1 2020 May 05, 2020	SELL	$6.55 - $14.76 $77,407 - $174,433	-11,818 Closed	0 $0
Q4 2019 Jan 30, 2020	BUY	$4.2 - $19.21 $49,635 - $227,023	11,818 New	11,818 $183,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.